Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 10/2019

01-10-2019 | Angiography | Original Paper

Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression

Authors: Aslı Vural, Dilbade Yıldız Ekinci, Ismail Umut Onur, Gülsüm Oya Hergünsel, Fadime Ulviye Yiğit

Published in: International Ophthalmology | Issue 10/2019

Login to get access

Abstract

Purpose

To investigate the extent of vascularization of the peripheral retina and vascular development patterns in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of bevacizumab (IVB) and compare fluorescein angiography (FA) findings of them to those seen in patients with type 2 ROP who have recovered spontaneously.

Methods

Between May 2014 and September 2016, patients with type 1 ROP who had a single 0.025 ml (0.625 mg) IVB were evaluated as study group. On the other hand, type 2 ROP patients with stage 2 or stage 3 ROP in zone II without plus disease on indirect ophthalmoscopy were not treated and included as a control group. The progression of ROP and vascularization of retina were evaluated by FA under sedation analgesia in all patients.

Results

Sixty-two eyes of 31 premature infants were included in the study: 36 eyes/18 patients were treated for type 1 ROP and 26 eyes/13 patients were followed conservatively with the diagnoses of type 2 ROP. In the last FA examination among the study group, vascular terminal was in zone II in 8 eyes/4 patients (22.22%) and in zone III in 28 eyes/14 patients (77.78%). Vascular terminal was in zone III in all eyes of the control group (100%). We noted circumferential vessels in 12 eyes/8 patients (33.3%) and 7 eyes/5 patients (26.92%) in the study and control groups, respectively. Abnormal branching was noticed in 13 eyes/7 patients (46.42%) in the control group, whereas it was not detected in the study group. Arteriovenous shunts were noted in 1 eye of a patient in the study group and in 5 eyes/4 patients in the control group. In 6 eyes/3 patients among the study group, we performed laser photocoagulation to the avascular retina because of profound vascular leakage.

Conclusion

Peripheral vascular abnormalities probably occur as a result of ROP itself because similar FA findings were detected both in type 1 and type 2 ROP patients with or without treatment, although significantly less in IVB-treated group. Retinal vascularization usually reaches the farthermost limits with time even though it slows down in eyes treated with IVB, indicating the importance of a longer follow-up.
Literature
1.
Stenkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK et al (1999) Childhood blindness. J AAPOS 3:26–32CrossRef
2.
Klufas MA, Chan RV (2015) Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years. J Pediatr Ophthalmol Strabismus 52:77–84CrossRef
3.
Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 133:391–397CrossRef
4.
Zhou Y, Jiang Y, Bai Y, Wen J, Chen L (2016) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefe’s Arch Clin Exp Ophthalmol 254:31–36CrossRef
5.
Pertl L, Steinwender G, Mayer C, Hausberger S, Pöschl EM, Wackernagel W, Wedrich A, El-Shabrawi Y, Haas A (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLOS ONE 10(6):e0129383CrossRef
6.
Wang H, Yang Z, Jiang Y, Flannery J, Hammond S, Kafri T, Vemuri SK, Jones B, Hartnett ME (2014) Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity. Investig Ophthalmol Vis Sci 55:737–744CrossRef
7.
Geisen P, Peterson LJ, Mariniuk D (2008) Neutralizing anti-body to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis 14:34557
8.
Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694CrossRef
9.
Lorenz B, Stieger K (2015) Retinopathy of prematurity recent developments in diagnosis and treatment. Expert Rev Ophthalmol 10:167–182CrossRef
10.
Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez-Barrios P (2008) Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 126(8):1161–1163CrossRef
11.
Mintz-Hittner HA, Kennedy KA, Chuang AZ, the BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity: preliminary results of the BEAT-ROP clinical trial. N Engl J Med 364:603–615CrossRef
12.
Tahija SG, Hersetyati R, Lam GC, Kusaka S, Mc Melamine PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98:507–512CrossRef
13.
Lalwani GA, Berrocal AM, Murray TG, Bruch M, Cardone S, Hess D, Johnson RA, Puliafito CA (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:13–18CrossRef
14.
Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831–838CrossRef
15.
Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, Fujikado T (2008) Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 92:1450–1455CrossRef
16.
Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL, Chan RV, Quiroz-Mercado H (2013) Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 33:329–338CrossRef
17.
Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Daida M (2017) Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina 37:97–111CrossRef
18.
Wallace DK, Wu KY (2013) Current and future trends in treatment of severe retinopathy of prematurity. Clin Perinatol 40:297–310CrossRef
19.
Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza B, Jonas JB (2013) Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155:1119–1124CrossRef
20.
Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, BEAT-ROP cooperative Group (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132:1327–1333CrossRef
21.
Chen Y-H, Chen S-N, Lien RI, Shih CP, Chao AN, Chen KJ, Hwang YS, Wang NK, Chen YP et al (2014) Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye 28:1080–1087CrossRef
22.
Mintz-hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123:1845–1855CrossRef
23.
Selvam S, Kumar T, Fruttiger M (2018) Retinal vasculature development in health and disease. Prog Retin Eye Res 63:1–19CrossRef
24.
Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M (2018) Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina 38:764–772CrossRef
25.
Blair MP, Shapiro MJ, Hartnett ME (2012) Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children. J Am Assoc Pediatr Ophthalmol Strabismus 16:234–237CrossRef
26.
Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000–1006CrossRef
27.
Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35:675–680CrossRef
28.
Isaac M, Mireskandari K, Tehrani N (2016) Does bevacizumab alter vascularization potential in retinopathy of prematurity? Ophthalmology 123:2042–2043CrossRef
29.
Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125:218–226CrossRef
Metadata
Title
Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression
Authors
Aslı Vural
Dilbade Yıldız Ekinci
Ismail Umut Onur
Gülsüm Oya Hergünsel
Fadime Ulviye Yiğit
Publication date
01-10-2019
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 10/2019
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-018-01064-7

Other articles of this Issue 10/2019

International Ophthalmology 10/2019 Go to the issue

Original Paper

Mechanism of interaction between ocular and nasal neurogenic inflammation in allergic rhinoconjunctivitis

Original Paper

Hydration of small leaking corneal perforations with cefuroxime

Original Paper

The involvement of the mGluR5-mediated JNK signaling pathway in rats with diabetic retinopathy

Original Paper

Use of commercially available sodium hyaluronate 0.18% eye drops for corneal epithelial healing in diabetic patients

Original Paper

Safety analysis and results of a borosilicate glass cartridge for no-touch graft loading and injection in Descemet membrane endothelial keratoplasty

Original Paper

Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography